Bai Jie, Xu Manman, Peng Fengling, Gong Junwei, Zhao Jinqiu, Song Xiaodong, Li Yongguo
Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fourth Department of Liver Disease (Difficult and Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.
Front Nutr. 2022 Dec 22;9:1071373. doi: 10.3389/fnut.2022.1071373. eCollection 2022.
The relationship between skeletal muscle mass index (SMI) and cirrhosis incidence in patients with non-cirrhotic acute-on-chronic (ACLF) has not been clarified. This study aimed to assess the predictive value of SMI on the incidence of long-term cirrhosis in male non-cirrhotic ACLF patients.
Male ACLF patients who were free of liver cirrhosis were retrospectively included in this study. Univariate and multivariate logistic analyses were conducted to determine the risk factors for the long-term (1-year) development of cirrhosis. The receiver operating characteristic curves (ROC) were used to assess the ability of SMI levels to predict the incidence of cirrhosis. Restricted triple spline (RCS) described the dose-response relationship between SMI and the risk of cirrhosis. Subgroup analysis was stratified by age (≤ 40 years and > 40 years).
A total of 230 subjects were included in this study, of whom 45.2% (104/230) were diagnosed with cirrhosis within 360 days. Patients who progressed to cirrhosis had a lower SMI [46.1 ± 6.9 versus 49.2 ± 6.5 cm/m, = 0.001] and a higher proportion of sarcopenia (19.2% versus 6.3%, = 0.003). In multivariate logistic regression, SMI remained a protective agent against 360-days progression to cirrhosis in males with ACLF after adjustment (OR 0.950, 95% CI: 0.908-0.994, < 0.05). SMI exerted a non-linear dose-dependent effect on the risk of cirrhosis. The area under the ROC curve (AUC) for the L3-SMI to predict the incidence of cirrhosis in male non-cirrhotic ACLF patients was 0.636 ( < 0.001). We observed significant differences in SMI among male ACLF patients in different age groups. Further subgroup analysis by age revealed that lower SMI was associated with the 1-year incidence of cirrhosis in male ACLF patients aged less than 40 years (OR 0.908, 95% CI: 0.842-0.979, < 0.05), whereas SMI did not affect the 1-year risk of cirrhosis in older subjects (age > 40 years).
A higher SMI represents an independent protective factor for developing long-term cirrhosis in male ACLF patients who do not experience cirrhosis, especially in those under 40 years of age.
非肝硬化慢加急性肝衰竭(ACLF)患者的骨骼肌质量指数(SMI)与肝硬化发生率之间的关系尚未明确。本研究旨在评估SMI对男性非肝硬化ACLF患者长期肝硬化发生率的预测价值。
本研究回顾性纳入了无肝硬化的男性ACLF患者。进行单因素和多因素逻辑回归分析以确定肝硬化长期(1年)发展的危险因素。采用受试者工作特征曲线(ROC)评估SMI水平预测肝硬化发生率的能力。受限三次样条曲线(RCS)描述了SMI与肝硬化风险之间的剂量反应关系。亚组分析按年龄(≤40岁和>40岁)分层。
本研究共纳入230名受试者,其中45.2%(104/230)在360天内被诊断为肝硬化。进展为肝硬化的患者SMI较低[46.1±6.9 vs 49.2±6.5 cm/m,P = 0.001],肌肉减少症的比例较高(19.2% vs 6.3%,P = 0.003)。在多因素逻辑回归中,调整后SMI仍然是男性ACLF患者360天内进展为肝硬化的保护因素(OR 0.950,95%CI:0.908 - 0.994,P < 0.05)。SMI对肝硬化风险具有非线性剂量依赖性影响。L3-SMI预测男性非肝硬化ACLF患者肝硬化发生率的ROC曲线下面积(AUC)为0.636(P < 0.001)。我们观察到不同年龄组男性ACLF患者的SMI存在显著差异。进一步按年龄进行亚组分析显示,较低的SMI与年龄小于40岁的男性ACLF患者1年肝硬化发生率相关(OR 0.908,95%CI:0.842 - 0.979,P < 0.05),而SMI对老年受试者(年龄>40岁)1年肝硬化风险没有影响。
较高的SMI是未发生肝硬化的男性ACLF患者发生长期肝硬化的独立保护因素,尤其是在40岁以下的患者中。